NIH PAR · NHLBI · R61, R33

PAR-25-026: NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)

Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards

Open for applicationsExpires Jan 8, 2027

The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the…

Full NOFO in the NIH Guide Apply on Grants.gov

NOFO number
PAR-25-026
Type
PAR
Activity code
R61R33
Primary institute
NHLBI · National Heart, Lung, and Blood Institute
Clinical trials
Required
Posted
Dec 5, 2024
Opens
Jan 3, 2025
Expires
Jan 8, 2027

PAR-25-026 due dates

No application due dates remain in the listed cycles. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.

Application due dates and review cycles for PAR-25-026
Application Due Date(s)Renewal / Resubmission / Revision (as allowed)AIDS - New/Renewal/Resubmission/Revision, as allowedScientific Merit ReviewAdvisory Council ReviewEarliest Start Date
February 03, 2025February 03, 2025May 07, 2025 *July 2025October 2025December 2025
June 04, 2025June 04, 2025September 07, 2025 *November 2025January 2026April 2026
October 02, 2025October 02, 2025January 07, 2026 *March 2026May 2026July 2026
February 03, 2026February 03, 2026May 07, 2026 *July 2026October 2026December 2026
June 04, 2026June 04, 2026Not ApplicableNovember 2026January 2027April 2027
October 02, 2026October 02, 2026Not ApplicableMarch 2027May 2027July 2027

Projects funded under PAR-25-026

NIH RePORTER lists 2 projects funded under PAR-25-026 in FY2022–FY2026, with $868K in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.

Projects funded

2

Distinct projects, FY2022–FY2026

New awards

2

Type 1 (new project) award records

NIH funding

$868K

Award dollars under PAR-25-026, FY2022–FY2026

Funding by fiscal year

Award records, new awards, and funding by fiscal year under PAR-25-026
Fiscal yearAward recordsNew awardsFunding
FY202200$0
FY202300$0
FY202400$0
FY202500$0
FY202622$868K

Institutions with the most funding

Funding institutes

  • NHLBI$868K · 2

Activity codes funded

  • R612 records

What its predecessor PAR-24-173 funded

PAR-25-026 reissues PAR-24-173. Its funding history is the best guide to who wins under this program: 1 project and $445K in FY2022–FY2026.

Projects funded

1

Distinct projects, FY2022–FY2026

New awards

1

Type 1 (new project) award records

NIH funding

$445K

Award dollars under PAR-24-173, FY2022–FY2026

Funding by fiscal year

Award records, new awards, and funding by fiscal year under PAR-24-173
Fiscal yearAward recordsNew awardsFunding
FY202200$0
FY202300$0
FY202400$0
FY202511$445K
FY202600$0

Institutions with the most funding

Funding institutes

  • NHLBI$445K · 1

Activity codes funded

  • R611 record

Most recent new awards

FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.

Participating institutes

2 NIH institutes and offices take applications under PAR-25-026. Contact the program officer at the institute that fits your research before applying.

  • NHLBI · National Heart, Lung, and Blood Institute
  • none

Related notices

  1. Mar 31, 2025 · NOT-OD-24-084

    This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…

  2. Aug 31, 2022 · NOT-OD-22-198

    Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.

  3. Aug 5, 2022 · NOT-OD-22-189

    Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.

Award terms

Application types allowed
NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Award budget
Application budgets in the R61 phase are limited to 250,000 in direct costs per year. Application budgets in the R33 phase should not exceed 1,515,000 in direct costs per year.
Project period
The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. The scope of the proposed project should determine the requested project period.      NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
Funds available and number of awards
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.

Related NOFOs

  • Reissue of PAR-24-173.
  • Companion NOFOs: PAR-25-025.

Other open NOFOs for R61, R33

Browse all open NIH NOFOs

About this page

GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.

Find who wins under this NOFO